Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | BCL2 | P10415 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144925 | 0.99 | LMNA (0.39) | LMNASMN1; SMN2NR3C1KEAP1NFE2L2 | |
| SCHEMBL28861359 | 0.84 | MAPT (0.41) | LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL27681020 | 0.82 | MAPT (0.42) | LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL10799202 | 0.81 | LMNA (0.40) | LMNASMN1; SMN2NR3C1KEAP1NFE2L2 | |
| SCHEMBL28161273 | 0.80 | LMNA (0.43) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5578301 | 0.80 | NR3C1 (0.35) | LMNANR3C1KEAP1NFE2L2CYP1A2 | |
| SCHEMBL28171927 | 0.80 | HTT (0.33) | LMNASMN1; SMN2NR3C1 | |
| SCHEMBL7132181 | 0.79 | ALDH1A1 (0.39) | LMNA | |
| SCHEMBL28209700 | 0.75 | MAPT (0.37) | LMNANR3C1KEAP1NFE2L2CYP1A2 | |
| SCHEMBL10797153 | 0.75 | LMNA (0.51) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813680-B1 | COMPOSITIONS FOR LIPASE ACTIVITY DETERMINATION AND METHOD OF DETERMINING ACTIVITY | ASAHI KASEI PHARMA CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7883862-B2 | comprising at least one diglyceride, a low concentration buffer, and a nonionic surfactant; for determining activity of pancreatic lipase or non-pancreatic lipases (such as hepatic lipase or lipoprotein lipase) in clinical laboratory tests | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20080038765-A1 | Composition for Lipase Activity Determination and Method of Determing Activity | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1813680-A1 | COMPOSITIONS FOR LIPASE ACTIVITY DETERMINATION AND METHOD OF DETERMINING ACTIVITY | Asahi Kasei Pharma Corporation (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038765-A1 | Composition for Lipase Activity Determination and Method of Determing Activity | LPL, GK, LIPG | LMNA 945/4885SMN1; SMN2 3013/4885NR3C1 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.